Fortress Biotech Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Fortress Biotech han disminuido a una tasa media anual de -14.6%, mientras que en la industria Biotechs los beneficios crecieron en un 15.5% anualmente. Los ingresos han ido creciendo a una tasa media de 18.9% al año.

Información clave

-14.6%

Tasa de crecimiento de los beneficios

4.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	18.9%
Rentabilidad financiera	n/a
Margen neto	-73.8%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

Fortress Biotech founded Cyprium's CUTX-101 nabs accelerated review for copper metabolism disorder

Dec 15

Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?

Dec 15

Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?

Nov 19

Fortress Biotech EPS misses by $0.02, misses on revenue

Nov 09

Desglose de ingresos y gastos

Cómo gana y gasta dinero Fortress Biotech. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:FBIO Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	85	-63	84	0
31 Dec 23	85	-69	91	0
30 Sep 23	62	-78	100	0
30 Jun 23	63	-96	108	0
31 Mar 23	64	-100	113	0
31 Dec 22	76	-95	114	0
30 Sep 22	78	-97	113	0
30 Jun 22	82	-93	105	0
31 Mar 22	81	-74	96	0
31 Dec 21	69	-65	87	0
30 Sep 21	64	-38	75	0
30 Jun 21	53	-33	68	0
31 Mar 21	44	-43	63	0
31 Dec 20	46	-47	61	0
30 Sep 20	43	-57	60	24
30 Jun 20	43	-54	59	39
31 Mar 20	43	-54	58	58
31 Dec 19	37	-40	56	81
30 Sep 19	34	-45	56	83
30 Jun 19	30	-51	54	87
31 Mar 19	27	-53	53	86
31 Dec 18	27	-73	53	87
30 Sep 18	-107	-61	38	77
30 Jun 18	-65	-69	45	73
31 Mar 18	-22	-72	48	69
31 Dec 17	17	-65	49	52
30 Sep 17	155	-74	57	49
30 Jun 17	109	-60	47	41
31 Mar 17	61	-55	39	36
31 Dec 16	16	-55	33	35
30 Sep 16	4	-50	32	30
30 Jun 16	3	-55	30	33
31 Mar 16	1	-49	26	29
31 Dec 15	1	-48	22	30
30 Sep 15	1	-40	18	25
30 Jun 15	1	-27	13	16
31 Mar 15	1	-25	12	15
31 Dec 14	0	-20	10	10
30 Sep 14	0	-26	10	14
30 Jun 14	0	-30	10	17
31 Mar 14	0	-36	10	22
31 Dec 13	0	-37	10	26
30 Sep 13	0	-36	10	24

Ingresos de calidad: FBIO actualmente no es rentable.

Margen de beneficios creciente: FBIO actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: FBIO no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 14.6% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de FBIO en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: FBIO no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-14.4%).

Rentabilidad financiera

Alta ROE: El pasivo de FBIO supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Fortress Biotech Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS misses analyst expectations

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Consensus EPS estimates fall by 93%, revenue upgraded

New major risk - Negative shareholders equity

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

New major risk - Revenue and earnings growth

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profitability

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Executive Chairman recently bought US$119k worth of stock

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Fortress Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $11 million.

Price target increased by 27% to US$67.50

Price target decreased by 14% to US$50.00

Forecast to breakeven in 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Fortress Biotech, Inc. has completed a Composite Units Offering.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

New major risk - Share price stability

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Price target decreased by 8.1% to US$3.55

Consensus revenue estimates fall by 20%

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2025

Consensus revenue estimates increase by 36%

Price target decreased by 13% to US$4.34

Consensus revenue estimates fall by 40%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Receives Second 180-Calendar Day Grace Period from Nasdaq to Regain Compliance with the Nasdaq Listing Rule 5550(a)(2)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 16% to US$5.10

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $13.896816 million.

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Price target decreased to US$5.92

Executive Chairman recently bought US$68k worth of stock

No longer forecast to breakeven

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insufficient new directors

Fortress Biotech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Executive Chairman recently bought US$70k worth of stock

Urica Therapeutics, Inc Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

Consensus revenue estimates fall by 13%

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Fortress Biotech, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Fortress Biotech Inc. Appoints David Jin as Chief Financial Officer

David Jin is the new finance chief of Fortress Biotech

Price target decreased to US$6.10

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 2000 Dynamic Index

Fortress Biotech, Inc.'s Subsidiary UR-1 Therapeutics, Inc. Doses First Patient in a Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Fortress Biotech, Inc. to Report Q1, 2022 Results on May 10, 2022

Fortress Biotech, Inc., Annual General Meeting, Jun 21, 2022

Price target decreased to US$6.60

Forecast breakeven date pushed back to 2024

Insufficient new directors

Consensus revenue estimates fall by 19%

Price target decreased to US$6.60

Forecast breakeven date pushed back to 2024

Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?

Fortress Biotech, Inc. Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV